MarketPulse

bitopertin

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.
IRONsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Disc Medicine Stock Plunges 22% After FDA Rejects Bitopertin Drug Application

FDA rejects Disc Medicine's bitopertin drug, triggering 22% stock decline and securities investigation into potential investor losses.
IRONsecurities fraudclass action lawsuit